The Italian Journal of Neurological Sciences

, Volume 4, Issue 4, pp 393–397 | Cite as

The diagnosis of thymoma in myasthenia gravis

  • Aarli J. A. 
Editorial

Abstract

Between 10 and 15 per cent of patients with myasthenia gravis (MG) have a thymoma. We have evaluated the possibility of detecting such tumours on the basis of clinical features, radiological findings and immunological tests in a group of 70 MG patients. The mean age at onset of myasthenic symptoms was 67.6 years in the thymoma group and 33.8 years in the non-thymoma group. Otherwise, the clinical picture was similar.

Radiological examination revealed a mediastinal mass in 2 patients. Six of the 70 MG sera contained antibodies to a citric acid (CA) extract of striated muscle. At thymectomy, a thymoma was found in these 6 patients. None of the remaining 64 patients had evidence of a thymoma. Antibodies to AChR were detected in 52 of the 70 MG sera.

There was no relation between titres of AChR and CA antibodies. Three out of 5 sera from non-MG patients with a thymoma contained CA antibodies.

Apparently, this assay is a valuable technique for the identification of a thymoma at an early stage.

Key-words

Myasthenia gravis thymus thymoma muscle antibodies indirect hemagglutination 

Sommario

Una percentuale variabile fino al 10 e al 15% dei miastenici è portatrice di timona. Vengono valutate le possibilità di diagnosticare i timomi sulla base dei dati clinici, radiologici e immunologici di un gruppo di 70 pazienti affetti da miastenia. L'età media di inizio dei sintomi miastenici risulta di 67.6 anni nel gruppo con timoma e di 33.8 anni nel gruppo senza timoma, mentre le caratteristiche cliniche sono del tutto sovrapponibili. Gli esami radiologici hanno rilevato una massa mediastinica in due pazienti. In 6 casi nel siero si sono posti in evidenza anticorpi nei confronti di un estratto in acido citrico di muscolo striato (CA) e alla timectomia in tutti questi 6 pazienti è stato riscontrato il timoma.

Anticorpi nei confronti AChR sono stati messi in evidenza in 52 dei 70 sieri.

Non si è vista una correlazione fra i titoli di anticorpi di AChR e di CA. 3 dei 5 sieri ricavati da pazienti non miastenici portatori di timoma contenevano anticorpi CA. Sembra quindi che questa tecnica sia valida per l'identificazione di un timoma allo stadio iniziale.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Aarli, J.A.:Myasthenia gravis. Antibodies to an acidsoluble antigen in striated muscle. Clin Exp Immunol 10: 453–461, 1972.PubMedGoogle Scholar
  2. [2]
    Aarli, J.A. andCloss, O.:Myasthenia gravis: Cross-striational fluorescence of muscle fibres mediated by Fc fragments. J Immunol 109: 271–274, 1972.PubMedGoogle Scholar
  3. [3]
    Aarli J.A., Lefvert, A.-.K., andTönder, O.:Thymomaspecific antibodies in sera from patients with myasthenia gravis demonstrated by indirect haemagglutination J Neuroimmunol 1 421–427, 1981.CrossRefPubMedGoogle Scholar
  4. [4]
    Aarli, J.A. andThunold, S.:Serological detection of thymoma in myasthenia gravis. Eur Neurol 20: 380–387, 1981.PubMedGoogle Scholar
  5. [5]
    Aarli, J.A. andTönder, O.:Antiglobulin consumption test with sera from patients with myasthenia gravis. Clin Exp Immunol 7: 11–21, 1970.PubMedGoogle Scholar
  6. [6]
    Blalock, A., Mason, M.F., Morgan, H.J., andRiven, S.S.:Myasthenia gravis and tumors of the thymic region. Report of a case in which the tumor was removed. Ann Surg X 110: 544–561, 1939.Google Scholar
  7. [7]
    Castleman, B.:The pathology of the thymus gland in myasthenia gravis. Ann NY Acad Sci 135: 496–505, 1966.PubMedGoogle Scholar
  8. [8]
    Djanian, A.Y., Beutner, E.H., Witebsky, E.:Tanned-cell hemagglutination test for detection of antibodies in sera of patients with myasthenia gravis. J Lab Clin Med 63: 60–70, 1964.PubMedGoogle Scholar
  9. [9]
    Hale, J.F. andScowen, E.F.: In:Thymic Tumours, 1–93, Lloyd-Luke (Medical Books) Ltd, London 1967.Google Scholar
  10. [10]
    Keesey, J., Bein, M., Mink, J., Sample, F., Sarti, D., Mulder, D., Herrmann, C., andPeter, J.B.:Detection of thymoma in myasthenia gravis. Neurology 30: 233–239, 1980.PubMedGoogle Scholar
  11. [11]
    Lefvert, A.K., Bergström, K., Matell, G., Osterman, P.O., andPirskanen, R.:Determination of acetylcholine receptor antibody in myasthenia gravis: Clinical usefulness and pathogenetic implications. J. Neurol Neurosurg Psychiatry 41: 394–403, 1978.PubMedGoogle Scholar
  12. [12]
    Legolvan, D.P. andAbell, M.R.:Thymomas. Cancer 39:2142–2157, 1977.PubMedGoogle Scholar
  13. [13]
    Levine, G.D.:Pathology of the thymus in myasthenia gravis: Current concepts. In: Dau, P.C. (ed): Plasmapheresis and the Immunobiology of Myasthenia Gravis, 113–123, Houghton Mifflin, Boston 1978.Google Scholar
  14. [14]
    Lisak, R.P. andBarchi, R.L.: Myasthenia Gravis, Volume 11 in the Series: Major Problems in Neurology, W.B. Saunders Company, Philadelphia 1982.Google Scholar
  15. [15]
    Namba, T. Himei, H., andGrob, D.:Complement fixing and tissue binding serum globulins in patients with myasthenia gravis, and their relation to muscle ribonucleoprotein. J Lab Clin Med 70: 258–272, 1967.PubMedGoogle Scholar
  16. [16]
    Oosterhuis, H.J.G.H., Bethlem J., andFeltkamp, T.E.W.:Muscle pathology, thymoma, and immunological abnormalities in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 31: 460–463, 1968.PubMedGoogle Scholar
  17. [17]
    Osserman, K.E.: In:Myasthenia gravis, 1–286, Grune & Stratton, New York and London, 1958.Google Scholar
  18. [18]
    Peers, J., McDonald, B.L., andDakwins, R.L.:The reactivity of the antistriational antibodies associated with thymoma and myasthenia gravis. Clin Exp Immunol 27: 66–73, 1977.PubMedGoogle Scholar
  19. [19]
    Shulman, S., Lang, R.W., Beutner, E.H., andWitebsky, E.:Precipitation of autoantibody in serum from patients with myasthenia gravis. Immunology 10: 289–303, 1966.PubMedGoogle Scholar
  20. [20]
    Strauss, A.J.L., Seegal, B.C., Hsu, J.C., Burkholder, P.M., Nastuk, W.L., andOsserman, K.E.:Immunofluorescence demonstration of muscle binding, complement fixing serum globulin fraction in myasthenia gravis. Proc Soc Expo Biol Med 105: 184–191, 1960.Google Scholar
  21. [21]
    Van der Geld, H. andOosterhuis, H.J.G.H.:Muscle and thymus antibodies in myasthenia gravis. Vox Sang 8: 196–204, 1963.PubMedGoogle Scholar

Copyright information

© Masson Italia Editori S.p.A. 1983

Authors and Affiliations

  • Aarli J. A. 
    • 1
  1. 1.Department of Neurology, School of MedicineUniversity of BergenNorway

Personalised recommendations